---
schema_version: "secwatch.filing_event.v1"
accession: "0001808665-25-000024"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:38:07.406592+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Assertio Q2 net product sales $28.8M, net loss $16.4M, cash rises to $98.2M

## Summary
- GAAP net loss $16.4M ($0.17 per share) vs $3.7M loss ($0.04) in prior year Q2.
- Adjusted EBITDA $5.6M, up from $3.1M; adjusted EPS $0.02 vs $0.01.
- Rolvedon sales $16.1M (+$1M YoY); Sympazan $3.2M (+$0.5M); Indocin $3.0M (down from $6.9M due to generic competition).
- Cash & investments $98.2M, up from $87.3M at Q1 2025; company narrows guidance.
- SG&A $17.0M, down from $18.4M, includes $2.4M employee retention tax credit benefit.

## SEC filing metadata
- accession: 0001808665-25-000024
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000180866525000024/0001808665-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000180866525000024/asrt-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808665-25-000024
- JSON: https://secwatch.observer/filing/0001808665-25-000024.json
- Plain text: https://secwatch.observer/filing/0001808665-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.